Diabetic Ketoacidosis (DKA) Global Market Report 2025

The diabetic ketoacidosis (DKA) market size has grown strongly in recent years. It will grow from $2.9 billion in 2024 to $3.16 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth during the historic period can be attributed to the rising prevalence of diabetes, delayed diagnosis of type 1 diabetes, poor adherence to insulin therapy, increasing obesity rates, and the lack of diabetes education programs.

The diabetic ketoacidosis (DKA) market size is expected to see strong growth in the next few years. It will grow to $4.37 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period is expected to be driven by advancements in insulin delivery systems, the increasing adoption of continuous glucose monitoring, greater awareness of diabetes-related complications, the expansion of telemedicine for diabetes management, and rising healthcare expenditures. Key trends during this period include the integration of artificial intelligence in diabetes care, the development of closed-loop insulin delivery systems, personalized medicine, cutting-edge technologies, and innovative therapies.

The rising prevalence of obesity is contributing to the expansion of the diabetic ketoacidosis (DKA) market. Obesity is a medical condition characterized by excessive accumulation of body fat, which can have adverse health effects and increase the risk of various diseases. The increase in obesity rates is driven by several factors, including unhealthy diets rich in processed foods, sugars, and fats, sedentary lifestyles with limited physical activity, prolonged screen time, and socioeconomic challenges such as limited access to affordable healthy food and healthcare. Obesity heightens the risk of diabetic ketoacidosis (DKA) by promoting insulin resistance and leading to the development of type 2 diabetes, which can result in poor blood sugar control and subsequent DKA episodes. For example, in March 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that approximately one in eight people worldwide were affected by obesity. This included 2.5 billion adults (aged 18 and older) who were overweight, with 890 million classified as obese. Among adults, 43% were overweight, and 16% were obese. Additionally, the number of overweight children under the age of five reached 37 million. Consequently, the growing prevalence of obesity is driving the expansion of the diabetic ketoacidosis market.

Leading companies in the diabetic ketoacidosis market are prioritizing the development of advanced technologies, such as continuous glucose monitoring tools, to enhance early detection, improve blood glucose and ketone level management, and ultimately reduce the frequency and severity of DKA episodes in individuals with diabetes. Continuous glucose monitoring (CGM) tools are devices designed to track glucose levels in real time, allowing individuals with diabetes to monitor and regulate their blood sugar levels effectively. For instance, in June 2022, Abbott Laboratories, a US-based medical device company, introduced an innovative continuous glucose-ketone monitoring system that enables real-time tracking of both glucose and ketone levels. This system integrates glucose and ketone monitoring, offering a comprehensive view of a patient's metabolic state. By measuring both metrics simultaneously, it facilitates the early detection of potential diabetic complications, such as diabetic ketoacidosis (DKA), before they become critical. Designed for continuous monitoring, the system provides frequent data updates without requiring manual testing, ensuring greater convenience for users.

In September 2023, Abbott Laboratories, a US-based medical device company, acquired Bigfoot Biomedical for an undisclosed amount. This acquisition strengthens Abbott’s diabetic care portfolio, which already features the globally recognized FreeStyle Libre continuous glucose monitoring technology. Bigfoot Biomedical Inc. is a US-based company specializing in medical technology for diabetic care.

Major players in the diabetic ketoacidosis (DKA) market are Merck And Co. Inc., Pfizer Inc., Sanofi S.A., Bristol Myers Squibb, Novartis AG, Roche Holding AG, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., B. Braun Medical Inc., Fresenius Kabi, Merit Pharmaceutical, Oramed Pharmaceuticals Inc., ICU Medical Inc., Tonghua Dongbao Pharmaceutical Co. Ltd., Wockhardt Ltd., Biocon Limited.

North America was the largest region in the diabetic ketoacidosis (DKA) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in diabetic ketoacidosis (DKA) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the diabetic ketoacidosis (DKA) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Diabetic ketoacidosis (DKA) is a serious complication of diabetes in which the body produces excessive blood acids known as ketones due to inadequate insulin levels. This condition can lead to dehydration, electrolyte imbalances, and potentially life-threatening complications. It is essential for diagnosing and managing severe metabolic imbalances in diabetic patients to prevent risks such as dehydration, organ failure, and coma.

The primary types of diabetic ketoacidosis (DKA) include pediatric diabetic ketoacidosis and adult diabetic ketoacidosis. Pediatric DKA occurs in children and adolescents with diabetes and is often triggered by insulin deficiency, infections, or other stress factors. Treatment options involve fluid replacement, electrolyte replenishment, and insulin therapy, including intermediate-acting and long-acting insulin. The available administration routes include oral, parenteral, and other methods. These treatments are distributed through various channels, both online and offline, and are utilized by multiple end users, such as hospitals, ambulatory care centers, and specialty clinics.

The diabetic ketoacidosis (DKA) market research report is one of a series of new reports that provides diabetic ketoacidosis (DKA) market statistics, including diabetic ketoacidosis (DKA) industry global market size, regional shares, competitors with diabetic ketoacidosis (DKA) market share, detailed diabetic ketoacidosis (DKA) market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic ketoacidosis (DKA) industry. This diabetic ketoacidosis (DKA) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The diabetic ketoacidosis (DKA) market includes revenues earned by entities by providing services such as blood glucose monitoring, ketone testing, and arterial blood gas analysis and related products such as blood glucose monitors, continuous glucose monitoring (CGM) devices, syringes, insulin pens, and insulin pumps. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.